Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Potential links between PCOS/PMOS and Alzheimer disease and related dementias.

Created on 13 Nov 2026

Authors

Mina Amiri, Armita Kakavand Hamidi, Daniel L Farkas, Richard P Buyalos, Ricardo Azziz

Published in

Journal of the Endocrine Society. Volume 10. Issue 11. Pages bvag206. Epub Oct 13, 2026.

Abstract

Polycystic ovary syndrome/polyendocrine metabolic ovarian syndrome (PCOS/PMOS) is a common endocrine disorder with significant metabolic and reproductive implications. Increasing attention has focused on its potential long-term neurological consequences, including possible links to cognitive impairment and Alzheimer disease (AD), through overlapping biological pathways.
We conducted a comprehensive PubMed search, from inception through October 2025, identifying studies on cognitive performance, brain structure and function, neurodegenerative biomarkers, and dementia risk in PCOS/PMOS patients.
Evidence supports multiple potential mechanistic pathways that could connect PCOS/PMOS to AD-relevant biology, such as insulin resistance (IR), chronic inflammation, hormonal dysregulation, and cardiovascular dysfunction. These pathways converge on neurodegeneration processes such as impaired Aβ clearance, tau hyperphosphorylation, oxidative stress, and cerebral metabolic deficits. Clinically, PCOS/PMOS patients exhibit mild but reproducible impairments in executive function and memory, alongside structural and functional brain alterations, including hippocampal and white matter changes, and altered network connectivity. However, these findings are influenced by coexisting metabolic dysfunction, and direct epidemiological evidence linking PCOS/PMOS to increased dementia incidence remains limited and inconsistent.
Current evidence indicates that any association between PCOS/PMOS and AD risk is likely mediated by metabolic comorbidities, particularly IR and obesity, rather than an independent effect of PCOS/PMOS itself. However, clinical evidence for increased PCOS/PMOS risk for cognitive vulnerability and dementia remain inconsistent and cognitive benefits from PCOS/PMOS-specific interventions are lacking. Clinical focus should therefore remain on optimizing metabolic health, while longitudinal and interventional studies are required to clarify long-term neurological relationships and outcomes.

PMID:
42872112
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement